View printer-friendly version |
<< Back |
Performance Highlights Flexibility of Cost Structure and Diversification of Business
Announces Amendment of Credit Agreement for Added Financial Flexibility
“We are taking timely, proactive steps to adapt the Company to the current environment, and to further bolster our strong financial position,” said
Preliminary Second Quarter Fiscal 2020 Results1
Preliminary GAAP Results
-
Revenue of approximately
$3.7 billion -
Operating Income of (
$106 million ) to$4 million -
EPS of (
$0.81 ) to ($0.39 )
Operating Income and EPS ranges include a potential non-cash impairment of
Preliminary Adjusted Results
-
Organic Revenue of approximately
$3.8 billion -
Adjusted Operating Income of
$157 million to$167 million -
Adjusted EPS of
$0.24 to$0.26 -
LTM Covenant Adjusted EBITDA of
$1,585 million to$1,595 million
Adjusted Operating Income, Adjusted EPS and Covenant Adjusted EBITDA are not impacted by the potential goodwill adjustment.
Preliminary Balance Sheet Results
-
Cash and Cash Equivalents of
$1,203 million -
Net Debt of
$6,763 million with no significant maturities due until 20232
1
2 As of
The impact of COVID-19 on the business for the fiscal second quarter was consistent with Aramark’s previous disclosure on
“Rapidly flexing the Company’s operating expenses and capital expenditures enables us to best navigate this challenging environment, while preserving our ability to provide the safe and hygienic food service, uniforms and facilities our existing and future clients will need to welcome back their employees, students, fans, visitors, and other consumers,” said Zillmer. “These actions are intended to help us quickly bring back our valued team members as we develop comprehensive re-opening plans, including new models for service delivery and customer engagement.”
Credit Agreement Amended
Earnings Conference Call
As previously announced,
Note Regarding Preliminary Results
The estimated fiscal 2020 second quarter results and liquidity are preliminary, unaudited and subject to completion, reflect management’s current views and may change as a result of management’s review of results and other factors. Such preliminary results for the fiscal 2020 second quarter are subject to the finalization and closing of our accounting books and records (which have yet to be performed), and should not be viewed as a substitute for full quarterly financial statements prepared in accordance with accounting principles generally accepted in the
About
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views as to future events and financial performance with respect to, without limitation, conditions in our industry, our operations, our economic performance and financial condition, including, in particular, statements by our CEO and including with respect to, without limitation, the impact of COVID-19 on our business, financial performance and operating results, including our preliminary second fiscal quarter 2020 results, anticipated effects of our adoption of new accounting standards, the expected impact of strategic portfolio actions, the benefits and costs of our acquisitions of each of
Forward-looking statements speak only as of the date made. All statements we make relating to our estimated and projected earnings, costs, expenditures, cash flows, growth rates, financial results and our estimated benefits and costs of our acquisitions are forward-looking statements. In addition, we, through our senior management, from time to time make forward-looking public statements concerning our expected future operations and performance and other developments. These forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those that we expected. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the cautionary statements. Some of the factors that we believe could affect our results or the costs and benefits of the acquisitions include without limitation: the severity and duration of the COVID-19 pandemic, the pandemic’s impact on the
Selected Operational and Financial Metrics
Adjusted Revenue (Organic) represents revenue growth, adjusted to eliminate the effects of material divestitures and the impact of currency translation.
Adjusted Operating Income represents operating income adjusted to eliminate the change in amortization of acquisition-related intangible assets; the impact of the change in fair value related to certain gasoline and diesel agreements; severance and other charges; the effect of divestitures (including the gain on the sale); merger and integration related charges; asset impairments, tax reform related employee reinvestments and other items impacting comparability.
Adjusted Net Income represents net income attributable to
Adjusted EPS represents Adjusted Net Income divided by diluted weighted average shares outstanding.
Covenant Adjusted EBITDA represents net income attributable to
We use Adjusted Revenue (Organic), Adjusted Operating Income, Adjusted Net Income, Adjusted EPS, and Covenant Adjusted EBITDA as supplemental measures of our operating profitability and to control our cash operating costs. We believe these financial measures are useful to investors because they enable better comparisons of our historical results and allow our investors to evaluate our performance based on the same metrics that we use to evaluate our performance and trends in our results. These financial metrics are not measurements of financial performance under generally accepted accounting principles, or GAAP. Our presentation of these metrics has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. You should not consider these measures as alternatives to revenue, operating income, net income, or earnings per share, determined in accordance with GAAP. Adjusted Revenue (Organic), Adjusted Operating Income, Adjusted Net Income, Adjusted EPS and Covenant Adjusted EBITDA as presented by us may not be comparable to other similarly titled measures of other companies because not all companies use identical calculations.
Reconciliation to Non-GAAP Measures
Three Months Ended |
||||||||||||||
|
|
|||||||||||||
Preliminary |
||||||||||||||
|
|
|||||||||||||
Consolidated Revenue (as reported) |
$ |
3,731,559 |
|
$ |
3,731,559 |
|
$ |
3,999,987 |
|
|||||
Effect of Currency Translation |
|
50,693 |
|
|
50,693 |
|
|
|||||||
Adjusted Revenue (Organic) |
$ |
3,782,252 |
|
$ |
3,782,252 |
|
$ |
3,999,987 |
|
|||||
Operating Income/(Loss) Range (as reported) |
$ |
(106,076 |
) |
$ |
3,924 |
|
$ |
122,835 |
|
|||||
Amortization of Acquisition-Related Intangible Assets |
|
29,125 |
|
|
29,125 |
|
|
28,657 |
|
|||||
Severance and Other Charges |
|
6,894 |
|
|
6,894 |
|
|
8,410 |
|
|||||
Merger and Integration Related Charges |
|
7,302 |
|
|
7,302 |
|
|
9,663 |
|
|||||
Goodwill Impairment |
|
200,000 |
|
|
100,000 |
|
|
- |
|
|||||
Gain on sale of Healthcare Technologies |
|
- |
|
|
- |
|
|
1,000 |
|
|||||
Tax Reform Related Employee Reinvestments |
|
- |
|
|
- |
|
|
65,455 |
|
|||||
Gains, Losses and Settlements impacting comparability |
|
19,838 |
|
|
19,838 |
|
|
311 |
|
|||||
Adjusted Operating Income |
$ |
157,083 |
|
$ |
167,083 |
|
$ |
236,331 |
|
|||||
Effect of Currency Translation |
|
336 |
|
|
336 |
|
|
|||||||
Adjusted Operating Income (Constant Currency) |
$ |
157,419 |
|
$ |
167,419 |
|
$ |
236,331 |
|
|||||
Operating Income Margin (as reported) |
|
-2.84 |
% |
|
0.11 |
% |
|
3.07 |
% |
|||||
Adjusted Operating Income Margin (Constant Currency) |
|
4.16 |
% |
|
4.43 |
% |
|
5.91 |
% |
Three Months Ended |
Three Months Ended |
|||||||||||
|
|
|||||||||||
Preliminary |
||||||||||||
|
|
|||||||||||
Net Income/(Loss) Attributable to |
|
(205,467 |
) |
|
(98,067 |
) |
|
29,353 |
|
|||
Adjustments: |
||||||||||||
Amortization of Acquisition-Related Intangible Assets |
|
29,125 |
|
|
29,125 |
|
|
28,657 |
|
|||
Severance and Other Charges |
|
6,894 |
|
|
6,894 |
|
|
8,410 |
|
|||
Merger and Integration Related Charges |
|
7,302 |
|
|
7,302 |
|
|
9,663 |
|
|||
|
|
200,000 |
|
|
100,000 |
|
|
- |
|
|||
Gain on Sale of Healthcare Technologies |
|
- |
|
|
- |
|
|
1,000 |
|
|||
Tax Reform Related Employee Reinvestments |
|
- |
|
|
- |
|
|
65,455 |
|
|||
Gains, Losses and Settlements impacting
|
|
19,838 |
|
|
19,838 |
|
|
311 |
|
|||
Effects of Refinancings and Other on Interest and Other Financing Costs, net |
|
20,883 |
|
|
20,883 |
|
|
- |
|
|||
Effect of Tax Legislation on Provision for Income Taxes |
|
8,848 |
|
|
8,848 |
|
|
(809 |
) |
|||
Tax Benefit Attributable to Former CEO Equity Award Exercises |
|
(21,768 |
) |
|
(21,768 |
) |
|
- |
|
|||
Tax impact related to shareholder contribution |
|
6,203 |
|
|
6,203 |
|
||||||
Tax Impact of Adjustments to Adjusted Net Income |
|
(12,052 |
) |
|
(12,052 |
) |
|
(29,240 |
) |
|||
Adjusted Net Income |
$ |
59,806 |
|
$ |
67,206 |
|
$ |
112,800 |
|
|||
Effect of Currency Translation, net of Tax |
|
(105 |
) |
|
(105 |
) |
|
- |
|
|||
Adjusted Net Income (Constant Currency) |
$ |
59,701 |
|
$ |
67,101 |
|
$ |
112,800 |
|
|||
Earnings Per Share (as reported) |
||||||||||||
Net Income/(Loss) Attributable to Aramark Stockholders (as reported) |
$ |
(205,467 |
) |
$ |
(98,067 |
) |
$ |
29,353 |
|
|||
Diluted Weighted Average Shares Outstanding |
|
254,443 |
|
|
254,443 |
|
|
250,347 |
|
|||
$ |
(0.81 |
) |
$ |
(0.39 |
) |
$ |
0.12 |
|
||||
Adjusted Earnings Per Share |
||||||||||||
Adjusted Net Income |
$ |
59,806 |
|
$ |
67,206 |
|
$ |
112,800 |
|
|||
Diluted Weighted Average Shares Outstanding |
|
254,443 |
|
|
254,443 |
|
|
250,347 |
|
|||
$ |
0.24 |
|
$ |
0.26 |
|
$ |
0.45 |
|
||||
Adjusted Earnings Per Share (Constant Currency) |
||||||||||||
Adjusted Net Income (Constant Currency) |
$ |
59,701 |
|
$ |
67,101 |
|
$ |
112,800 |
|
|||
Diluted Weighted Average Shares Outstanding |
|
254,443 |
|
|
254,443 |
|
|
250,347 |
|
|||
$ |
0.23 |
|
$ |
0.26 |
|
$ |
0.45 |
|
Preliminary LTM |
LTM |
|||||||||||
|
|
|
||||||||||
|
|
|
|
|
||||||||
Consolidated Sales |
$ |
15,947.2 |
|
$ |
15,947.2 |
|
$ |
16,150.5 |
|
|||
Net Income Attributable to Aramark Stockholders (as reported) |
$ |
108.8 |
|
$ |
216.2 |
|
$ |
528.1 |
|
|||
Interest and other financing costs, net |
|
347.2 |
|
|
347.2 |
|
|
351.0 |
|
|||
(Benefit)/Provision for income taxes |
|
86.8 |
|
|
89.4 |
|
|
87.6 |
|
|||
Depreciation and amortization |
|
589.9 |
|
|
589.9 |
|
|
608.1 |
|
|||
Share-based compensation expense |
|
26.3 |
|
|
26.3 |
|
|
88.0 |
|
|||
Unusual or non-recurring (gains) and losses |
|
- |
|
|
- |
|
|
(156.3 |
) |
|||
Pro forma EBITDA for equity method investees |
|
6.7 |
|
|
6.7 |
|
|
13.2 |
|
|||
Pro forma EBITDA for certain transactions |
|
15.7 |
|
|
15.7 |
|
|
(11.1 |
) |
|||
Seamless |
|
- |
|
|
- |
|
|
- |
|
|||
Other |
|
404.0 |
|
|
304.0 |
|
|
185.8 |
|
|||
Covenant Adjusted EBITDA |
$ |
1,585.4 |
|
$ |
1,595.3 |
|
$ |
1,694.3 |
|
|||
Debt to Covenant Adjusted EBITDA |
||||||||||||
Total Debt |
$ |
7,966.0 |
|
$ |
7,966.0 |
|
$ |
7,190.6 |
|
|||
Less: Cash and cash equivalents |
$ |
1,203.0 |
|
$ |
1,203.0 |
|
$ |
195.4 |
|
|||
Net debt |
$ |
6,763.0 |
|
$ |
6,763.0 |
|
$ |
6,995.2 |
|
|||
Adjusted EBITDA |
$ |
1,585.4 |
|
$ |
1,595.3 |
|
$ |
1,694.3 |
|
|||
Debt/ Covenant Adjusted EBITDA |
|
4.3 |
|
|
4.2 |
|
|
4.1 |
|
|||
Covenant Adjusted EBITDA margin |
|
9.9 |
% |
|
10.0 |
% |
|
10.5 |
% |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005546/en/
Media Inquiries
Cutler-Karen@aramark.com
Investor Inquiries
Kissell-Felise@aramark.com
Source: